#Dividend #Shareholders #United Kingdom #TC BioPharm #Buckie

TC BioPharm's Upcoming Shareholder Meeting

TC BioPharm (Holdings) PLC, a clinical-stage biotechnology firm primarily focused on developing innovative gamma-delta T cell therapies for cancer treatment, has made an important announcement for its investors. The company's Board of Directors has sanctioned a special dividend, proposing to distribute 0.25 American Depositary Shares (ADSs) for each ADS currently held by shareholders, contingent on their approval during an upcoming general meeting.

The crucial event is set to take place on Monday, December 30, 2024, at 2:00 PM (UK time) at The Seafield Arms Hotel located in Cullen, Buckie, Scotland. This meeting serves as a significant opportunity for shareholders to express their opinions and vote on the proposed dividend, marking a pivotal moment for the company's commitment to its investors.

According to the current plans, the special dividend will be officially declared on the same day as the general meeting and will be disbursed to shareholders holding TC BioPharm stock by the close of trading on January 2, 2025. Details regarding the specific payment date for the American Depositary Shares will be provided later, ensuring transparency and clarity for shareholders.

Bryan Kobel, the CEO of TC BioPharm, expressed his enthusiasm about the dividend announcement, highlighting the unwavering support from shareholders during challenging times within the capital markets. He noted the company's recent struggles with false claims and misinformation targeting its market position. "Our shareholders deserve to be rewarded for their steadfastness, and while we cannot accelerate regulatory actions or combat fraud single-handedly, we firmly believe that this dividend represents a step forward in enhancing shareholder value," he remarked.

The ongoing commitment to return value to shareholders remains a priority for TC BioPharm, as highlighted by Kobel's statement regarding the company’s focus on achieving operational excellence in the forthcoming year, 2025. The proposed dividend not only reflects the company's appreciation but also showcases its determination to enhance its market standing amidst external challenges.

Shareholders are encouraged to review the details regarding the dividend in the forthcoming notice and explanatory notes for the general meeting, which will be freely accessible on the investor relations section of the company's official website (TC BioPharm Investor Relations) as well as on the SEC's website at www.sec.gov.

As a leader in gamma-delta T cell therapy, TC BioPharm has been actively engaged in clinical studies, particularly observing promising results in treating conditions like acute myeloid leukemia. The company's dedication to pioneering treatment options is evident, and it continues to pave the way for advancements in biopharmaceuticals.

Forward-Looking Statements
The release also contains forward-looking statements as outlined under the Private Securities Litigation Reform Act of 1995. It’s essential for investors to recognize that these statements may involve various risks and uncertainties that could impact the company's actual performance and future results. They are encouraged to consult TC BioPharm's annual reports and other filings accessible via the SEC and the company’s investor relations website for a comprehensive understanding of the possible risks.

Conclusion

With the upcoming general meeting, TC BioPharm seeks to bolster its relationship with shareholders while encouraging active participation in the decision-making process regarding dividends. This initiative, alongside its commitment to innovative cancer therapies, positions the company for a promising trajectory as it enters 2025.